Tenax Therapeutics Valuation
| TENX Stock | USD 5.36 0.03 0.56% |
At this time, the company appears to be undervalued. Tenax Therapeutics has a current Real Value of $5.94 per share. The regular price of the company is $5.36. Our model measures the value of Tenax Therapeutics from inspecting the company fundamentals such as Shares Outstanding of 3.41 M, return on equity of -1.14, and Shares Owned By Institutions of 47.95 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Tenax Therapeutics' valuation include:
Price Book 0.1879 | Enterprise Value 9.2 M | Enterprise Value Ebitda (0.14) | Forward PE 0.299 |
Undervalued
Today
Please note that Tenax Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Tenax Therapeutics is based on 3 months time horizon. Increasing Tenax Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Tenax Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tenax Stock. However, Tenax Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.36 | Real 5.94 | Target 5.5 | Hype 5.35 | Naive 5.79 |
The intrinsic value of Tenax Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Tenax Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Tenax Therapeutics helps investors to forecast how Tenax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tenax Therapeutics more accurately as focusing exclusively on Tenax Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Tenax Therapeutics' intrinsic value based on its ongoing forecasts of Tenax Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Tenax Therapeutics' closest peers.
Tenax Therapeutics Cash |
|
Tenax Valuation Trend
Analysing the historical paterns of Tenax Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Tenax Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Tenax Therapeutics Total Value Analysis
Tenax Therapeutics is at this time estimated to have valuation of 9.17 M with market capitalization of 18.27 M, debt of 500.9 K, and cash on hands of 7.23 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Tenax Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.17 M | 18.27 M | 500.9 K | 7.23 M |
Tenax Therapeutics Asset Utilization
One of the ways to look at asset utilization of Tenax is to check how much profit was generated for every dollar of assets it reports. Tenax Therapeutics has a negative utilization of assets of -0.66 %, losing $0.006609 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Tenax Therapeutics shows how discouraging it operates for each dollar spent on its assets.Tenax Therapeutics Ownership Allocation
The market capitalization of Tenax Therapeutics is $18.27 Million. 30% of Tenax Therapeutics outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Tenax Therapeutics Profitability Analysis
Net Loss for the year was (7.71 M) with profit before overhead, payroll, taxes, and interest of 0.About Tenax Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Tenax Therapeutics. We calculate exposure to Tenax Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tenax Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -7.6 K | -7.2 K | |
| Pretax Profit Margin | (328.57) | (312.15) | |
| Operating Profit Margin | (345.72) | (328.44) | |
| Net Loss | (328.57) | (312.15) | |
| Gross Profit Margin | 0.72 | 0.53 |
Tenax Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 248.4 K | |
| Forward Price Earnings | 0.299 |
Tenax Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Tenax Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Tenax we look at many different elements of the entity such as Tenax's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Tenax Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Tenax Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Tenax Therapeutics' worth.Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.